Back to search results

Genomic Profiling for Solid Tumors and Hematologic Cancers

This study, called "Genomic Profiling in Cancer Patients," is looking at whether certain genes in cancer cells are abnormal, which are called mutations. Most mutations happen after birth and are not inherited. The goal is to test your cancer for these mutations using leftover tumor tissue from a past surgery or biopsy. You would also provide a blood, cheek swab, or saliva sample for comparison. This study is for people with a history of cancer or those undergoing a procedure to check for cancer. Researchers want to find out how often "actionable" mutations (those that might guide treatment) occur, measured at 1 year.

Study design
This is an observational study with a planned enrollment of 200 participants. It is not specified if it's randomized or blinded.
What's involved
You would provide leftover tumor tissue from a previous surgery or biopsy. You would also provide a blood, cheek swab, or saliva sample.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, frequency of "actionable" oncogenic mutations, is measured at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01775072

Genomic Profiling in Cancer Patients

Recruiting
Not specifiedAll AgesObservational
Memorial Sloan Kettering Cancer Center
~200 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:molecular profiling of tumorsClinical Germline Analysis

At a glance

Recruiting sites
16 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
frequency of "actionable" oncogenic mutations
Measured over 1 year

Conditions

Solid Tumors
Hematologic Cancers

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT01775072

Where you'd take part

This study runs at 18 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Baptist Alliance MCI

    Miami, Floridastudy coordinator listed

    Recruiting

  • Hartford Healthcare Cancer Institute @ Hartford Hospital

    Hartford, Connecticutstudy coordinator listed

    Not yet recruiting

  • Kings County Hopsital Center

    Brooklyn, New Yorkstudy coordinator listed

    Recruiting

  • Lehigh Valley Health Network

    Allentown, Pennsylvaniastudy coordinator listed

    Recruiting

  • Medisys Health Network (Data Collection Only)

    Richmond Hill, New Yorkstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Bergen

    Montvale, New Jerseystudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Solit, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

David Solit, MD
646-888-2641
Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with a history of cancer or patients without a documented cancer history undergoing a surgical procedure, endoscopy, biopsy, or liquid biopsy (for example cell free DNA testing) to confirm or exclude a cancer diagnosis, or
Any participant having a test or procedure that has the potential to provide a specimen that can be banked for future research purposes, or
Any participant who has already had a diagnostic or therapeutic procedure that has yielded tissue, blood or other bodily fluids presently in the archive but who has not yet been approached to participate is also eligible.
Patients must be successfully registered to Part A of MSKCC IRB# 12-245
Prior written approval for patient consent obtained from the Principal/Co-Principal Investigator of MSKCC IRB # 12-245.
Patient must be receiving ongoing care at MSK or a CHERPn/ Alliance/Affiliate site or have previously consulted with an MSK physician.
Patient must have successfully consented to Part A of this study.
Patients with no personal cancer history at increased risk for cancer development due to family history, molecular cancer marker, know carrier status of a gene associated with increased cancer risk or prior/ongoing environmental exposures or lifestyle factors.

Exclusion

Unwilling or unable to provide informed consent.

What this trial measures

  • frequency of "actionable" oncogenic mutations1 year

    "Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.